Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ: SRRK) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET. A live webcast and 90-day replay will be accessible via the Investors section of the company’s website.
Scholar Rock (NASDAQ: SRRK) updated the expected timing of the CHMP opinion on its apitegromab marketing authorisation application (MAA) for treating children and adults with spinal muscular atrophy (SMA). The EMA review includes the Catalent Indiana fill-finish facility and is awaiting the FDA’s post-inspection classification update following an April 2026 site inspection.
If the FDA reclassifies Catalent Indiana, a CHMP opinion is expected later in 2026. If not, Scholar Rock plans to work with the EMA to advance the MAA using its second fill-finish facility, already included in the apitegromab BLA under FDA review with a September 30, 2026 PDUFA date.
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards covering an aggregate of 118,586 shares of common stock granted to eleven newly hired employees under its 2022 Inducement Equity Plan. The grants consist of stock options for 33,987 shares and restricted stock units (RSUs) for 84,599 shares.
According to Scholar Rock, the inducement stock options have an exercise price of $54.70, equal to the July 13, 2026 closing price. Options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments; RSUs vest in four equal annual installments, all subject to continued service.
Scholar Rock (NASDAQ: SRRK) will report its second quarter 2026 financial results on Thursday, August 6, 2026, before U.S. financial markets open. The company will host a management-led conference call and live webcast at 8:00 a.m. ET, with online and telephone access plus a webcast replay available for about 90 days.
Scholar Rock (NASDAQ: SRRK) will present new clinical data and research updates on its neuromuscular portfolio at Cure SMA’s 2026 Annual SMA Research & Clinical Care Meeting and the 2026 International Research Congress on FSHD.
Presentations cover apitegromab data from the Phase 3 SAPPHIRE trial and Phase 2 FORGE study.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards for an aggregate 134,345 shares of common stock to eleven new employees under its 2022 Inducement Equity Plan, in line with Nasdaq Listing Rule 5635(c)(4).
Awards comprise 50,936 stock options at a $43.80 exercise price and 83,409 RSUs with time-based vesting.
Scholar Rock (NASDAQ: SRRK) announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET.
A live and archived webcast will be available on the company’s investor relations website.
Scholar Rock (NASDAQ: SRRK) announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 11:40 a.m. ET.
A live and replay webcast will be accessible via the Investors section of the company’s website.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards for an aggregate 38,481 common shares to six new employees under its 2022 Inducement Equity Plan.
The grants include stock options for 12,061 shares at a $48.35 exercise price and 26,420 restricted stock units, with multi-year vesting tied to continued service.
Scholar Rock (NASDAQ: SRRK) reported Q1 2026 results and regulatory progress for apitegromab. The FDA accepted the apitegromab BLA with a PDUFA date of Sept 30, 2026, covering two U.S. fill-finish sites. Catalent reinspection is complete; facility classification is expected within 90 days.
The second fill-finish site is on track to supply commercial product in early Q3 2026. Scholar Rock reported cash, cash equivalents, and marketable securities of $479.9 million as of March 31, 2026, reflecting a $100.0 million debt draw and $98.0 million net ATM proceeds. Q1 net loss was $105.5 million.